search
Back to results

2 Neurofeedback Protocols in the Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents

Primary Purpose

ADHD

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
SMR (12-15 Hz)
alpha band (8 -12Hz)
Sponsored by
Fondation Lenval
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ADHD focused on measuring ADHD, neurofeedback

Eligibility Criteria

8 Years - 15 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children or teenagers between 8 and 15 years old included
  • Subject with mixed-type ADHD (attention deficit hyperactivity disorder) diagnosed by a specialist physician in the field and according to Diagnosis and Statistics of Mental Disorders-5 (DSM-5) criteria.
  • Subject of any psychotropic treatment for at least 15 days before inclusion
  • Subject committing not to take any treatment during the study period, nor to participate in another therapeutic treatment in parallel.
  • Subject available and pledging to honor the two weekly neurofeedback sessions for 15 consecutive weeks, and be available for symptom monitoring at 6 months.
  • Child benefiting from a Social Security scheme.

Non Inclusion Criteria:

  • Neurological disorders (epilepsy)
  • Trouble of the autistic spectrum
  • Active disorder without hyperactivity (TDA)
  • Bad understanding of the French language
  • Low Intellectual Level (IQ <70 Cognitive Assessment)
  • Lack of understanding of the constraints inherent in the protocol
  • Inability to comply with the constraints of the study throughout its duration

Exclusion Criteria:

  • premature termination of participation, withdrawal of the patient's voluntary informed consent
  • Investigator's or sponsor's decision
  • Withdrawal of consent of subjects or legal guardians

Sites / Locations

  • Hôpitaux pédiatriques de Nice CHU LenvalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

SMR Sensory Motor Rhythm (12-15 Hz)

the alpha band (8 -12Hz)

Arm Description

3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region

3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region

Outcomes

Primary Outcome Measures

Effectiveness of a neurofeedback protocol on the symptoms of Attention-Deficit with Hyperactivity Disorder (ADHD)
ADHD symptoms will be assessed using the clinician version of the 18-item Attention-Deficit with Hyperactivity rating scale IV (ADHD-RS). Each item is scored on a 0-3 scale with 0 representing the absence of the behavior/symptom and 3 representing the very frequent and impairing behavior/symptom over the last months. Two subscales compose ADHD-RS: 9-item Inattention subscale (range: 0-27) and a Hyperactivity-Impulsivity subscale (range: 0-27). The total ADHD-RS score is the sum of the two subscale scores and ranges from 0 to 54. Effectiveness of a neurofeedback protocol on the training capacity will be defined as a decrease of at least 30% the ADHD-RS total score between baseline, after 15 workout sessions of neurofeedback (2 sessions per week) and another 15 workout sessions of neurofeedback (2 sessions per week). Patients completing the study will therefore have undergone 30 workout sessions of neurofeedback

Secondary Outcome Measures

Stability of change in ADHD symptoms after 6-month follow-up
The ADHD-RS total score will be rated after a 6-month follow-up period of time to assess the stability of changes compared with the last workout session of neurofeedback. Stability is defined as absolute variation of 10% of the ADHD-RS total score.
Scores on Inattention and Hyperactivity-Impulsivity components of ADHD during a neurofeedback protocol
The changes on the Inattention and Hyperactivity-Impulsivity subscores of the ADHD-RS will be described: baseline, after 15 workout sessions of neurofeedback (2 sessions per week) and after another 15 workout sessions of neurofeedback (2 sessions per week). We expect a significant diminution of either or both scores compared with baseline (repeated testing)..
Sleep quality during a neurofeedback protocol using a questionnaire
Sleep quality will be assessed by the 19-item Pittsburgh Sleep Quality Index (PSQI) questionnaire filled by the patient with support of his/her parents at baseline, after 15 workout sessions of neurofeedback, after another 15 workout sessions of neurofeedback and after a 6-month follow-up period of time. The first four items are open while the next 15 items are rated on a 0 to 3 scale. Seven component scores are generated and further added to provide an overall score ranging from 0 to 21, lower scores denoting a healthier sleep quality.
Executive functions rated during a neurofeedback protocol
Executive functions are assessed using the Behavioral Performance Evaluation Inventory questionnaire (BRIEF) at baseline, after another 15 workout sessions of neurofeedback and after a 6-month follow-up period of time. When possible, both the Parent and Teacher versions of the BRIEF are filled out. The BRIEF questionnaire counts 86 items groups in eight non-overlapping clinical scales (Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor) and two validity scales (Inconsistency and Negativity) and two validity scales. The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite. Scale scores are converted to T-scores providing information about the child's individual scores relative to the scores of other respondents in the standardization sample
Clinical Improvement during a neurofeedback protocol and after 6-month follow-up
Clinical severity will be assessed at baseline using Guy's Global Clinical Impression scale (CGI-S).The clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Ratings range to 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). Clinical improvement will be assessed at baseline, after 15 workout sessions of neurofeedback after 30 workout sessions of neurofeedback and after a 6-month follow-up period of time. The clinician rates how much the patient's illness has improved or worsened relative to a state at the beginning of the protocol. Ratings range to 1 (Very much improved) to 7 (Very much worse).
Computerized measures of attention and impulsivity during a neurofeedback protocol
A task-oriented computerised assessment of attention-related problem, the Conners Continuous Performance Test 3rd Edition (CPT-3), will be performed at baseline, after 15 workout sessions of neurofeedback, after another 15 workout sessions of neurofeedback and after a 6-month follow-up period of time. Lasting 14 minutes of time, the CPT-3 provides objective information about inattentiveness, impulsivity, sustained attention, and vigilance. The patient's results are compared with a large normative sample of 1,400 subjects

Full Information

First Posted
November 7, 2017
Last Updated
September 28, 2023
Sponsor
Fondation Lenval
search

1. Study Identification

Unique Protocol Identification Number
NCT04378699
Brief Title
2 Neurofeedback Protocols in the Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents
Official Title
Comparison of 2 Neurofeedback Protocols in the Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 21, 2018 (Actual)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondation Lenval

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Attention Deficit Disorder with or without Hyperactivity (ADD / H) is a public health problem since it has short and long-term consequences, affects about 5% of children of school age but remains unknown and therefore under- diagnostic. The investigator will performed a controlled and randomized research to compare the effects of two neurofeedback protocols on the repercussions of Attention Deficit AD / Hyperactivity Disorder (HD) symptoms, in particular the hyperactivity on which the improvements reported in the literature are less with usual protocols.
Detailed Description
Attention deficit disorder with or without hyperactivity (ADD / H) is a public health problem since it has short and long-term consequences, affects about 5% of children of school age but remains unknown and therefore under- diagnostic. In the symptomatic triad of inattention, impulsivity and hyperactivity, there is often a psychopathological disorder, a learning and / or sleep disorder. Medication treatment with methylphenidate is the reference in terms of prescription to reduce the symptoms of AD / HD. However, the limitations of its long-term effectiveness, tolerance of side effects, and parental distrust of psychostimulant treatment are gradually opening the door to new therapeutic approaches. Neurofeedback is considered by the scientific world as a promising and effective neurocognitive learning technique in the treatment of Attention Deficit Disorder with Hyperactivity ADHD and several neurological and psychiatric disorders. Its principle is to increase the patient's ability to regulate his own brain activity, captured by an ElectroEncephaloGram (EEG), after visual and auditory feedback. In this controlled and randomized research, the investigator will compare the effects of two neurofeedback protocols on the repercussions of AD / HD symptoms, in particular the hyperactivity on which the improvements reported in the literature are less with usual protocols. Seventy children and adolescents aged 7 to 15 in two groups will benefit from thirty neurofeedback sessions each, either on a so-called Sensory Motor Rhythm (SMR) protocol or on a protocol called Upper Alpha. To date, no studies have identified the effects of a NF Upper Alpha protocol on improving sleep, hyperactivity and comorbidities in patients with ADHD in a controlled and randomized manner. nor on personality dimensions related to the processes of self-regulation of the patient involved in Neurofeedback (NF) treatment. The investigator expects superior clinical improvement of ADHD symptoms and sleep disorders in the NF upper alpha training group in patients not following any parallel drug or therapy regimen. The investigator expects stability of the effects of treatment after several months of stopping neurofeedback sessions, without taking or recovery of psychostimulant. This research protocol would make it possible for dozens of children and adolescents to benefit from an alternative treatment (in the absence of placebo conditions) in order to achieve a clinical improvement of at least 30% of their patients. symptoms related to AD / HD, as well as to develop a field of research still little investigated in France. On the other hand, parents would be more likely to accept effective neurofeedback treatment than psychostimulant treatment, especially since it may have side effects. In addition, the validation of clinical improvements following a neurofeedback protocol aimed at increasing the relative power of alpha waves at frontal sites would be encouraging for clinical practice and future research in this area.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ADHD
Keywords
ADHD, neurofeedback

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
single-center interventional biomedical research with direct individual benefit, randomized with two active arms (without placebo)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
70 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SMR Sensory Motor Rhythm (12-15 Hz)
Arm Type
Experimental
Arm Description
3 X 10 SMR workout sessions (12-15 Hz) C4 unipolar placement, central region
Arm Title
the alpha band (8 -12Hz)
Arm Type
Experimental
Arm Description
3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
Intervention Type
Other
Intervention Name(s)
SMR (12-15 Hz)
Intervention Description
SMR training sessions (12-15 Hz) C4 unipolar placement, central region
Intervention Type
Other
Intervention Name(s)
alpha band (8 -12Hz)
Intervention Description
3 x 10 training sessions of the higher frequencies of the alpha band (8 -12Hz), unipolar placement Fz, fronto-central region
Primary Outcome Measure Information:
Title
Effectiveness of a neurofeedback protocol on the symptoms of Attention-Deficit with Hyperactivity Disorder (ADHD)
Description
ADHD symptoms will be assessed using the clinician version of the 18-item Attention-Deficit with Hyperactivity rating scale IV (ADHD-RS). Each item is scored on a 0-3 scale with 0 representing the absence of the behavior/symptom and 3 representing the very frequent and impairing behavior/symptom over the last months. Two subscales compose ADHD-RS: 9-item Inattention subscale (range: 0-27) and a Hyperactivity-Impulsivity subscale (range: 0-27). The total ADHD-RS score is the sum of the two subscale scores and ranges from 0 to 54. Effectiveness of a neurofeedback protocol on the training capacity will be defined as a decrease of at least 30% the ADHD-RS total score between baseline, after 15 workout sessions of neurofeedback (2 sessions per week) and another 15 workout sessions of neurofeedback (2 sessions per week). Patients completing the study will therefore have undergone 30 workout sessions of neurofeedback
Time Frame
scores between baseline and after 15 weeks
Secondary Outcome Measure Information:
Title
Stability of change in ADHD symptoms after 6-month follow-up
Description
The ADHD-RS total score will be rated after a 6-month follow-up period of time to assess the stability of changes compared with the last workout session of neurofeedback. Stability is defined as absolute variation of 10% of the ADHD-RS total score.
Time Frame
scores between 15 weeks and after 6 months
Title
Scores on Inattention and Hyperactivity-Impulsivity components of ADHD during a neurofeedback protocol
Description
The changes on the Inattention and Hyperactivity-Impulsivity subscores of the ADHD-RS will be described: baseline, after 15 workout sessions of neurofeedback (2 sessions per week) and after another 15 workout sessions of neurofeedback (2 sessions per week). We expect a significant diminution of either or both scores compared with baseline (repeated testing)..
Time Frame
scores between baseline and after 7weeks and after 15 weeks
Title
Sleep quality during a neurofeedback protocol using a questionnaire
Description
Sleep quality will be assessed by the 19-item Pittsburgh Sleep Quality Index (PSQI) questionnaire filled by the patient with support of his/her parents at baseline, after 15 workout sessions of neurofeedback, after another 15 workout sessions of neurofeedback and after a 6-month follow-up period of time. The first four items are open while the next 15 items are rated on a 0 to 3 scale. Seven component scores are generated and further added to provide an overall score ranging from 0 to 21, lower scores denoting a healthier sleep quality.
Time Frame
between baseline and after 15 weeks and after 6 months
Title
Executive functions rated during a neurofeedback protocol
Description
Executive functions are assessed using the Behavioral Performance Evaluation Inventory questionnaire (BRIEF) at baseline, after another 15 workout sessions of neurofeedback and after a 6-month follow-up period of time. When possible, both the Parent and Teacher versions of the BRIEF are filled out. The BRIEF questionnaire counts 86 items groups in eight non-overlapping clinical scales (Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor) and two validity scales (Inconsistency and Negativity) and two validity scales. The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite. Scale scores are converted to T-scores providing information about the child's individual scores relative to the scores of other respondents in the standardization sample
Time Frame
scores between baseline and after 15 weeks and after 6 months
Title
Clinical Improvement during a neurofeedback protocol and after 6-month follow-up
Description
Clinical severity will be assessed at baseline using Guy's Global Clinical Impression scale (CGI-S).The clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Ratings range to 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). Clinical improvement will be assessed at baseline, after 15 workout sessions of neurofeedback after 30 workout sessions of neurofeedback and after a 6-month follow-up period of time. The clinician rates how much the patient's illness has improved or worsened relative to a state at the beginning of the protocol. Ratings range to 1 (Very much improved) to 7 (Very much worse).
Time Frame
Evolution between baseline and after 15 weeks and after 6 months
Title
Computerized measures of attention and impulsivity during a neurofeedback protocol
Description
A task-oriented computerised assessment of attention-related problem, the Conners Continuous Performance Test 3rd Edition (CPT-3), will be performed at baseline, after 15 workout sessions of neurofeedback, after another 15 workout sessions of neurofeedback and after a 6-month follow-up period of time. Lasting 14 minutes of time, the CPT-3 provides objective information about inattentiveness, impulsivity, sustained attention, and vigilance. The patient's results are compared with a large normative sample of 1,400 subjects
Time Frame
at baseline, after 15 weeks and after 6months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children or teenagers between 8 and 15 years old included Subject with mixed-type ADHD (attention deficit hyperactivity disorder) diagnosed by a specialist physician in the field and according to Diagnosis and Statistics of Mental Disorders-5 (DSM-5) criteria. Subject of any psychotropic treatment for at least 15 days before inclusion Subject committing not to take any treatment during the study period, nor to participate in another therapeutic treatment in parallel. Subject available and pledging to honor the two weekly neurofeedback sessions for 15 consecutive weeks, and be available for symptom monitoring at 6 months. Child benefiting from a Social Security scheme. Non Inclusion Criteria: Neurological disorders (epilepsy) Trouble of the autistic spectrum Active disorder without hyperactivity (TDA) Bad understanding of the French language Low Intellectual Level (IQ <70 Cognitive Assessment) Lack of understanding of the constraints inherent in the protocol Inability to comply with the constraints of the study throughout its duration Exclusion Criteria: premature termination of participation, withdrawal of the patient's voluntary informed consent Investigator's or sponsor's decision Withdrawal of consent of subjects or legal guardians
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hervé MD CACI
Phone
04 92 03 05 69
Ext
0033
Email
caci.h@pediatrie-chulenval-nice.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Olivier Mr BAILET
Phone
04 92 0 34011
Ext
0033
Email
bailet.o2@chu-nice.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hervé MD CACI
Organizational Affiliation
Hôpitaux Pédiatriques de Nice CHU-LENVAL
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpitaux pédiatriques de Nice CHU Lenval
City
Nice
ZIP/Postal Code
06200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hervé MD CACI, MD
Phone
04 92 03 05 69
Ext
0033
Email
caci.h@pediatrie-chulenval-nice.fr
First Name & Middle Initial & Last Name & Degree
Hervé MD CACI, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

2 Neurofeedback Protocols in the Treatment of Attention Deficit Hyperactivity Disorder in Children and Adolescents

We'll reach out to this number within 24 hrs